Immunotherapy with modified extract of Olea europaea pollen
BiologicalSubcutaneous immunotherapy with modified extract of Olea europaea. A subcutaneous monthly treatment.
NCT Number: NCT00831025
The objective of this trial is to assess the clinical efficacy of a modified allergen extract of Olea europaea pollen in the treatment of patients affected by allergic rhinitis/rhinoconjunctivitis (with or without episodic asthma) induced by hypersensitivity to olea europaea pollen, evaluating the Score regarding Symptoms and consumption of the medication.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 3
Hospital El Tomillar, Dos Hermanas, Sevilla, Spain
Immunotherapy is a specific treatment for allergic diseases. Unlike conventional pharmacological treatment, immunotherapy is the only treatment that could modify the natural course of allergic disease. This is a prospective double-blind placebo-controlled study with two arms of treatment: placebo and active.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subcutaneous immunotherapy with modified extract of Olea europaea. A subcutaneous monthly treatment.
Placebo for subcutaneous monthly administration
Time frame: 2 years
Time frame: 2 years
Time frame: 2 years
Time frame: 2 years
Time frame: 2 years
Time frame: 2 years
Time frame: 2 years
Time frame: 2 years
Time frame: 2 years
Laboratorios Leti, S.L.
Industry
Multicenter, Randomised, Double-blind Placebo-controlled, Subcutaneous Immunotherapy Clinical Trial With Depigmented and Polymerized Allergen Extract of Olea Europaea Pollen in Patients With Hypersensitivity to Olea Pollen
Acronym: OLEA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06916884
Allergic Rhinitis, Hypersensitivity
Mexico City, Mexico
View Trial DetailsNCT05324397
Chronic Rhinitis, Infections
Birmingham, Alabama, United States
View Trial DetailsNCT05591989
Chronic Rhinitis, Infections
Birmingham, Alabama, United States
View Trial DetailsNCT07556393
Allergic Rhinitis, Allergic Rhinitis Due to Allergens
Kingston, Ontario, Canada
View Trial Details